Novel Anti-Hypertensive Treatment & NSCLC Drug Among New EU Filings

The European Medicines Agency has added five new drugs to its latest monthly list of medicines that are under review for potential EU marketing approval.

Patients with uncontrolled blood pressure are at risk of major cardiovascular events. • Source: Shutterstock

The European Medicines Agency has started reviewing a new batch of drugs, including aprocitentan and sugemalimab, for potential pan-EU marketing authorization.

Aprocitentan is Idorsia/Janssen Biotech’s novel dual endothelin receptor antagonist for the treatment of patients with resistant hypertension.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography